I think there is such a great opportunity and the field is moving very fast in the precision and personalized approach and for the preventive strategy. Of course, there is a lot that needs to be done for our patients, but the fact that there is new treatment also opens the door to combination therapy to also add, in addition to targeted treatment, a multimodal approach including also, like physical activity stimulation, and so on...
I think there is such a great opportunity and the field is moving very fast in the precision and personalized approach and for the preventive strategy. Of course, there is a lot that needs to be done for our patients, but the fact that there is new treatment also opens the door to combination therapy to also add, in addition to targeted treatment, a multimodal approach including also, like physical activity stimulation, and so on. So it’s really a new area that we are able to have a more holistic approach for prevention because we also are able to identify at a very early stage the individual at risk. So, to be able to target the individual at risk with a new approach, as we have done, for example, with the ALZEVIT study of the APOE at-risk population. But there is also the ability to detect amyloid positivity using blood-based biomarkers and also using digital biomarkers. So, it’s totally a new area that is arriving. Four parts still need to be totally confirmed and totally implemented in the healthcare system. But there is a lot of innovation and the combination between what we know already of the disease, of the biomarkers, and the innovative part of digital and AI will also allow us to have a more holistic approach and think of the patient, individual at risk, as an individual and not as a group, as we have done before.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
